Metabolon Awards Two Fully Funded Metabolomics Projects to Researchers
News Jun 30, 2016
Metabolon, Inc. has announced that it has awarded fully funded discovery projects to two life sciences researchers, following a competitive application and selection process. The winners are Charles Ruegg, Ph.D., from Eli Lilly and Company and Thaddaeus May, M.D., from Baylor College of Medicine.
Dr. Ruegg’s project is titled “Mechanism of Action: An Exploration of a Novel Inhibitor in Human Plasma Samples Following 28 Days of Treatment.” Dr. May’s project, “Metabolomics of Kwashiorkor Malnutrition,” will focus on understanding the cause of this severe form of acute childhood malnutrition.
“Our goal is to enhance their research through metabolomics to find answers for life-threatening diseases and human health concerns,” said Jay Tolley, Vice President and General Manager of Pharmaceutical and Life Sciences at Metabolon. “We congratulate the award recipients for the work they have done thus far and look forward to successful collaborations on both projects.”
The pilot projects include a metabolomics analysis of all major metabolite classes, including complex lipids. Metabolon will also perform statistical analysis and a thorough biological interpretation of the results.
Metabolomics is the study of small molecules called metabolites and an integral technology for understanding the function of biological systems. By providing a comprehensive picture of the biochemistry, metabolomics is advancing precision medicine and research for translational science, biomarker identification and the study of disease and treatment.
Modified Form of Botox Could Replace Opioids as Treatment for Chronic PainNews
A modified form of botulinum toxin gives long-lasting pain relief in mice without adverse effects and, in time, could replace opioid drugs as a safe and effective way of treating chronic pain, according to new research.READ MORE
Genetic Factors Leading to Rare Bone Fusion Disorder IdentifiedNews
Genome sequencing establishes multiple genes responsible for a rare condition that cause bone fusionREAD MORE
5th edition of the International Conference Clinical Oncology and Molecular Diagnostics
Jun 17 - Jun 18, 2019